|
1
|
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
|
N Engl J Med
|
2007
|
8.41
|
|
2
|
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
|
Lancet Oncol
|
2013
|
4.30
|
|
3
|
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
|
N Engl J Med
|
2014
|
2.99
|
|
4
|
Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13.
|
Blood
|
2009
|
2.07
|
|
5
|
Advanced hepatic ablation technique for creating complete cell death: irreversible electroporation.
|
Radiology
|
2010
|
2.06
|
|
6
|
Quality of discharge practices and patient understanding at an academic medical center.
|
JAMA Intern Med
|
2013
|
2.03
|
|
7
|
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.
|
Blood
|
2014
|
2.01
|
|
8
|
CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma.
|
Blood
|
2004
|
1.82
|
|
9
|
Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma.
|
Blood
|
2010
|
1.79
|
|
10
|
NADPH oxidase 4 promotes endothelial angiogenesis through endothelial nitric oxide synthase activation.
|
Circulation
|
2011
|
1.68
|
|
11
|
Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure.
|
Blood
|
2008
|
1.63
|
|
12
|
Perioperative outcomes comparing patient controlled epidural versus intravenous analgesia in gynecologic oncology surgery.
|
Gynecol Oncol
|
2009
|
1.53
|
|
13
|
Comprehensive quality of discharge summaries at an academic medical center.
|
J Hosp Med
|
2013
|
1.30
|
|
14
|
Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma.
|
J Clin Oncol
|
2008
|
1.23
|
|
15
|
Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma.
|
Haematologica
|
2010
|
1.18
|
|
16
|
Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival.
|
Biol Blood Marrow Transplant
|
2011
|
1.10
|
|
17
|
Effect of noncompetitive proteasome inhibition on bortezomib resistance.
|
J Natl Cancer Inst
|
2010
|
1.09
|
|
18
|
Hepatocytes express functional NOD1 and NOD2 receptors: a role for NOD1 in hepatocyte CC and CXC chemokine production.
|
J Hepatol
|
2010
|
1.00
|
|
19
|
Refractive errors in twin studies.
|
Twin Res Hum Genet
|
2006
|
1.00
|
|
20
|
Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance.
|
J Clin Oncol
|
2005
|
0.99
|
|
21
|
Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma.
|
Leuk Lymphoma
|
2013
|
0.94
|
|
22
|
Age 40 years and under does not confer superior prognosis in patients with multiple myeloma undergoing upfront autologous stem cell transmplant.
|
Biol Blood Marrow Transplant
|
2009
|
0.87
|
|
23
|
Autologous stem cell transplant is an effective therapy for carefully selected patients with AL amyloidosis: experience of a single institution.
|
Br J Haematol
|
2013
|
0.86
|
|
24
|
Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone.
|
Leuk Lymphoma
|
2010
|
0.85
|
|
25
|
Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma.
|
Br J Haematol
|
2014
|
0.83
|
|
26
|
Oligoclonal and monoclonal bands after single autologous stem cell transplant in patients with multiple myeloma: impact on overall survival and progression-free survival.
|
Leuk Lymphoma
|
2014
|
0.83
|
|
27
|
Cyclophosphamide and prednisone induction followed by cyclophosphamide mobilization effectively decreases the incidence of engraftment syndrome in patients with POEMS syndrome who undergo stem cell transplantation.
|
Am J Hematol
|
2011
|
0.82
|
|
28
|
A phase I study of the metal ionophore clioquinol in patients with advanced hematologic malignancies.
|
Clin Lymphoma Myeloma Leuk
|
2012
|
0.80
|
|
29
|
Two distinct syndromes of lymphoma-associated AL amyloidosis: a case series and review of the literature.
|
Am J Hematol
|
2010
|
0.80
|
|
30
|
How diagnostic is ultrasound-guided neck mass biopsy (fine-needle capillary sampling biopsy technique)?: evaluation of 132 nonthyroid neck mass biopsies with pathologic analysis over 7 years at a single institution.
|
J Ultrasound Med
|
2009
|
0.79
|
|
31
|
PRIMA-1Met induces apoptosis in Waldenström's Macroglobulinemia cells independent of p53.
|
Cancer Biol Ther
|
2015
|
0.79
|
|
32
|
Bortezomib as a treatment option in patients with Waldenström macroglobulinemia.
|
Clin Lymphoma Myeloma Leuk
|
2010
|
0.78
|
|
33
|
Rapidity and quality of response to steroid-based induction therapy, without the addition of novel agents, does not affect post transplant outcomes in multiple myeloma.
|
Clin Lymphoma Myeloma Leuk
|
2012
|
0.78
|
|
34
|
Lenalidomide plus melphalan without prednisone for previously untreated older patients with multiple myeloma: a phase II trial.
|
Clin Lymphoma Myeloma Leuk
|
2012
|
0.78
|
|
35
|
Thalidomide-prednisone maintenance following autologous stem cell transplant for multiple myeloma: effect on thrombin generation and procoagulant markers in NCIC CTG MY.10.
|
Br J Haematol
|
2014
|
0.77
|
|
36
|
Prognostic relevance of 6q deletion in Waldenström's macroglobulinemia: a multicenter study.
|
Clin Lymphoma Myeloma
|
2009
|
0.77
|
|
37
|
Effectiveness of pre-counseling genetic education workshops at a large urban community health center serving low-income Chinese American women.
|
J Genet Couns
|
2011
|
0.77
|
|
38
|
The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.
|
Bioorg Med Chem Lett
|
2011
|
0.76
|
|
39
|
Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma.
|
Br J Haematol
|
2014
|
0.76
|
|
40
|
Marked discordance for myopia in female monozygotic twins.
|
Clin Experiment Ophthalmol
|
2006
|
0.76
|
|
41
|
Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for the treatment of secondary plasma cell leukemia.
|
Leuk Lymphoma
|
2014
|
0.75
|
|
42
|
3.0 Tesla vs 1.5 Tesla breast magnetic resonance imaging in newly diagnosed breast cancer patients.
|
World J Radiol
|
2013
|
0.75
|
|
43
|
Conflicts of interest, authorship, and disclosures in industry-related scientific publications.
|
Mayo Clin Proc
|
2010
|
0.75
|
|
44
|
Intermittent granulocyte colony-stimulating factor for neutropenia management in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone.
|
Leuk Lymphoma
|
2014
|
0.75
|
|
45
|
Efficacy of thalidomide-based therapy following lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma.
|
Am J Hematol
|
2013
|
0.75
|
|
46
|
Concordant bilateral Duane's Retraction Syndrome (type 1) in female monozygotic twins.
|
Clin Experiment Ophthalmol
|
2006
|
0.75
|
|
47
|
Autologous stem cell transplant for light chain deposition disease: incorporating bortezomib to the induction therapy.
|
Am J Hematol
|
2012
|
0.75
|